September 11, 2019, 15:45 - 16:00
Type 2 diabetes (T2D) is a chronic and multifactorial disease, which becomes a significant challenge for healthcare systems due to the epidemic number of affected patients as well as related comorbidities. Assessment of patient health, with focus on signatures associated with disease progression, could contribute to optimization of treatment strategies. Determination of deregulated physiological processes of the body, beyond standard analytical methods, could be achieved by deployment of multi-omics approaches (e.g. genomics, transcriptomics, proteomics and metabolomics). However, little is known about the relevance of the information driven by those methods in context of T2D. Hence, we have conducted metabolomics, proteomics, glycomics, and transcriptomics, using different analytical platforms on 369 samples including 181 controls and 188 T2D. We further evaluated the data from each analytical platform and its association with T2D. Our studies lead to identification of molecular signatures as well as pathways associated with T2D and its progression.